Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
GlycoMimetics Inc
GKOCurrent price
0.14 EUR
0 EUR (0.00%)
Last closed
0.17 USD
Company
www.glycomimetics.com
ISIN
US38000Q1022
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
10 962 280 USD
Yield for 12 month
-87.77 %
1Y
3Y
5Y
10Y
15Y
GKO
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Address: 9708 Medical Center Drive, Rockville, MD, United States, 20850
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.75 USDP/E ratio
–Dividend Yield
–Current Year
+10 000 USD
Last Year
+74 925 USD
Current Quarter
–
Last Quarter
–
Current Year
-143 301 USD
Last Year
+74 925 USD
Current Quarter
-12 423 USD
Last Quarter
-14 620 USD
Key Figures GKO
1 year
3 years
5 years
10 years
EBITDA
-40 783 964 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-59.25 %
PEG Ratio
–
Return On Equity TTM
-104.49 %
Wall Street Target Price
0.75 USD
Revenue TTM
10 000 USD
Book Value
0.31 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
75 000 USD
Earnings per share
-0.6 USD
Diluted Eps TTM
-0.6 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics GKO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GKO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation GKO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
555.3967
Price Sales TTM
1096.228
Enterprise Value EBITDA
-0.4834
Price Book MRQ
0.5464
Financials GKO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators GKO
For 52 weeks
0.16 USD
3.53 USD
50 Day MA
0.22 USD
Shares Short Prior Month
2 312 921
200 Day MA
1.52 USD
Short Ratio
1.27
Shares Short
1 932 208
Short Percent
4.32 %
BeatStart